In HCC, artemisinin disrupts cellular bioenergetics and inactivates Hippo-YAP signaling [252], while artesunate exacerbates AFAP1L2-SRC-FUNDC1 axis-dependent mitophagy and mitigates sorafenib resistance [78]. The gene discussed is AFAP1L2; the disease is hepatocellular carcinoma.